Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AT-527 in Combination with Daclatasvir in Chronic HCV Infection
2019-001431-31Phase 2Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bemnifosbuvir and daclatasvir in chronic hepatitis C (CHC), sponsored by Atea Pharmaceuticals. Primary endpoints: Safety and tolerability of AT-527 in combination with daclatasvir and Proportion of subjects with HCV RNA below lower limit of quantification (LLOQ). Started Apr 2019; status: completed.
02
Drugs
bemnifosbuvirdaclatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2019-001431-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001431-31.